News

As AI takes the programming world by storm, experienced devs are still the gold standard — and they're better off without AI ...
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...
While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.
Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...
Morgan Stanley (NYSE:MS) initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming ...
In his brilliant satire of office culture, The Art of Asking Your Boss for a Raise, Georges Perec offered some startlingly ...
For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.
I’m not a programmer. But I’ve been creating my own software tools with help from artificial intelligence.
Recursion keeps you in the realm of functions, and ideally, you want to use pure functions (meaning, functions without side-effects).